SCHEMBL23976004

SCHEMBL23976004

CN(CC(=O)Nc1cccc(F)c1)c1nc(-c2cc(OCCNC(=O)OC(C)(C)C)ccn2)nc2c1CCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.39
ITK Q08881 3/20 0.38
EGFR P00533 2/20 0.38
PDE10A Q9Y233 1/20 0.37
HPGD P15428 1/20 0.36
LMNA P02545 2/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
CTDSP1 Q9GZU7 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PDK2 Q15119 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30225253 1.00 TDP1 (0.39) TDP1ITKEGFRPDE10AHPGD
SCHEMBL23975666 0.91 TDP1 (0.41) TDP1PDE10AHPGDLMNAKMT2A
SCHEMBL30118634 0.91 TDP1 (0.41) TDP1PDE10AHPGDLMNAKMT2A
SCHEMBL30118605 0.88 PDE10A (0.42) TDP1PDE10AHPGDLMNAKMT2A
SCHEMBL23976581 0.88 PDE10A (0.42) TDP1PDE10AHPGDLMNAKMT2A
SCHEMBL23976005 0.88 PDE10A (0.41) TDP1PDE10AHPGDLMNAKMT2A
SCHEMBL30118837 0.88 PDE10A (0.43) TDP1PDE10AHPGDLMNAKMT2A
SCHEMBL23976613 0.88 PDE10A (0.43) TDP1PDE10AHPGDLMNAKMT2A
SCHEMBL30118651 0.88 PDE10A (0.41) TDP1PDE10AHPGDLMNAKMT2A
SCHEMBL23975963 0.87 TDP1 (0.40) TDP1PDE10AHPGDLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2022-12-15 US disclosed
WO-2021222483-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed
WO-2021222363-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 TDP1 1304/4885ITK 2347/4885EGFR 4203/4885
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI TDP1 2891/4885ITK 1462/4885EGFR 3578/4885
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI TDP1 2891/4885ITK 1462/4885EGFR 3578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.